



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63592

Title: Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

Reviewer's code: 03664527

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-01-29

Reviewer chosen by: Jia-Ping Yan

Reviewer accepted review: 2021-02-19 05:19

Reviewer performed review: 2021-02-19 11:06

Review time: 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

As early as 2011, the author proposed a novel nanosome SapC-DOPS . This substance can inhibit the proliferation of tumor cells and enhance the toxicity of gemcitabine, but the effect in vivo is not clear, and additional in vivo tests are needed.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63592

Title: Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

Reviewer's code: 05106105

Position: Editorial Board

Academic degree: MD

Professional title: Chief Technician, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-01-29

Reviewer chosen by: Jia-Ping Yan

Reviewer accepted review: 2021-02-18 10:01

Reviewer performed review: 2021-02-21 03:17

Review time: 2 Days and 17 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Comments to the Author In your review, you describe the mechanisms and efficacy of SapC-DOPS, a novel phosphatidylserine (PS) biomarker targeted nanodrug, alone and in combination with other treatment modalities such as gemcitabine (GEM), Abraxane and radiation for the treatment of pancreatic ductal adenocarcinoma (PDAC) tumors in vivo, which has not been reviewed in the literature. Your reference documentation is very comprehensive and the review concludes almost all conditions that may have something to do with SapC-DOPS. I can imagine how much work you have done for this professional review. I recommend that you give a final polish to your writing to keep your message as concise as possible. For example, there's too much in the introduction and current therapy sections. I really appreciate your great work and it's my great honor to read this paper.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63592

Title: Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

Reviewer's code: 03821481

Position: Peer Reviewer

Academic degree: MD, MSc

Professional title: Attending Doctor, Doctor, Instructor, Surgeon

Reviewer's Country/Territory: Portugal

Author's Country/Territory: United States

Manuscript submission date: 2021-01-29

Reviewer chosen by: Jia-Ping Yan

Reviewer accepted review: 2021-02-18 08:53

Reviewer performed review: 2021-03-17 19:04

Review time: 27 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear author, Very interesting and well written review. It clearly demonstrates possible benefits of SapS-DPOS not only from a therapeutic stand point but also as a possible imaging agent. Its synergist effect with current chemotherapy agents and even in combination with radiation on tumor cells makes this a drug a very promising new addition to currently available medications. I would like to know if there are any studies regarding combination with mFOLFIRINOX as it is first line treatment in fit patients. As you say in your introduction gemcitabine is a first line drug but not "generally the first line", particularly in monotherapy. Also, please review Table 1 as per AJCC 8th edition (please refer to attachment). Congratulations.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63592

Title: Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

Reviewer's code: 03821481

Position: Peer Reviewer

Academic degree: MD, MSc

Professional title: Attending Doctor, Doctor, Instructor, Surgeon

Reviewer's Country/Territory: Portugal

Author's Country/Territory: United States

Manuscript submission date: 2021-01-29

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2021-04-14 05:21

Reviewer performed review: 2021-04-17 15:07

Review time: 3 Days and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Thank you for the changes. You can find attached a suggestion for the AJCC prognostic groups as there are still some minor details that are not in accordance with the 8th edition. Congratulations.